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ABSTRACT 
Lysozyme, a model protein, was used to study the effects of excipients 
(lactitol, copovidone and gelucire 44/14) on the protein biological 
activity. Three different concentrations (0.1, 0.5 and 10 %w/v) of the 
excipients were used with a relatively high (10%w/v) lysozyme 
concentration. Analytical methods such as UV spectroscopy and 
fluorescence technique were used to study the effect of excipients on 
protein biological stability and integrity. The data obtained from analysis showed that 
gelucire 44/14 had a disadvantage effect on lysozyme stability as a single excipient. 
However, by combining gelucire 44/14 with lactitol, the protein activity was preserved. Also, 
the combination of lactitol and copovidone preserved the integrity and activity of 6% 
lysozyme to a great extent. Different excipients stabilised proteins to different degree. As 
conclusion, there is no excipient that works well for even one type of proteins. The most 
suitable excipient for each particular protein is found by extensive research studying the 
activity and stability of the protein in the presence of excipients. High efficacy and accuracy 
analytic methods should be used in order to give reliable information on protein stability and 
integrity. 
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INTRODUCTION  
The limited stability of proteins and peptides in aqueous media is becoming the major 
problem in the effective improvement and commercialisation of ideal protein pharmaceutical 
dosage forms suitable for protein delivery. Improving proteins stability in the pharmaceutical 
formulations has an impact on protein-based therapeutic drugs and vaccines on world health. 
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Development of proteins as therapeutic dosage forms has attracted several researchers during 
the last decades (see for example; Qodratnama et al., 2015; Gu et al., 2015;  Mudassir et al., 
2015; Zhang et al., 2014; Haj-Ahmad et al., 2013; Jiang et al., 2005). Most of the critical 
steps in the pharmaceutical processing of proteins is to maintain proteins biological activity, 
folded state and stability during the pharmaceutical processing, periods of storage, 
transportation and administration to patients (Wu et al., 2015; Dobson, 2003; Change and 
Hershenson, 2002; Manning et al., 1989; Privalov, 1979). Therefore, in order to preserve the 
biological function of proteins, the physically and chemically properties of proteins should be 
controlled (Haj-Ahmad et al., 2013).  
 
Several pharmaceutical methods were utilised for protein delivery, such systems like;  
niosomes (e.g. delivery of lysozyme by niosomes, see for example Haj-Ahmad et al., 2010), 
liposomes (e.g. delivery of insulin via liposomes, see for example Niu et al., 2011), 
electrospun nanofibers (e.g. bovine serum albumin, see for example Esfahani et al., 2015) and 
electrospryed nanoparticles (e.g. delivery of insulin, see for example Bakhshi et al., 2011) 
mucoadhesive tablets (e.g. delivery of oxytocin, see for example Metia and Bandyopadhyay, 
2008). However, all of these pharmaceutical formulations produces dry solid product that 
might be affected by the moisture upon storage.  
  
Ideally, a pure protein formulation is the supreme formulation that everyone is looking for. 
However, it is impossible to launch a pharmaceutical formulation that just contain the native 
protein due to the difficulty of protein purification, protein stability and high probability of 
contamination (Change and Hershenson, 2002) especially in liquid form (Malik et al., 2013). 
Accordingly, several attempts have documented using various excipients in order to maintain 
the integrity of proteins in solid form (see for example; Liu et al., 2014, Santana et al., 2014) 
and liquid forms (see for example; Maddux et al., 2014; Malik et al., 2013). Proteins are not 
stable enough to be handled as a liquid formulation, meaning high risk of protein 
denaturation and degradation (Bock et al., 2012). 
 
To elucidate the impact of some additives on protein activity and conformational stability in 
liquid interface, it is necessary to examine the biological activity, tertiary and secondary 
structure stability in solution forms. A clear understanding of the protein-excipient 
interactions would help in the development of protein-based drugs (Kamerzell et al., 2011). 
Moreover, choosing the right excipient is critical to stabilise the protein during storage time. 
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Some excipients were reported to have a negative influence on proteins activity such as 
mannitol in liquid form (Rochelle et al., 2005; Kang et al., 2002).  
 
In this work, lysozyme (a globular protein with antibacterial activity) was used as a model 
protein as it is well characterised in the literatures (Haj-Ahmad et al., 2013, Elkordy et al., 
2008, Rosenberger, 1996 and Roxby and Tanford, 1971). The aim of this research is to study 
the effects of some excipients (lactitol, copovidone and gelucire 44/14) on the stability of 
lysozyme as a model protein in solution forms and to study the protein-excipient relationship 
using different excipients. Lactitol (sugar alcohol), copovidone (1-vinyl-2-pyrrolidone and 
vinyl acetate copolymer) and gelucire 44/14 (a hydrophilic excipient with Hydrophilic-
Lipophilic Balance of 14 and a melting temperature of 44 °C (Roussin et al., 1997) were used 
to access the influences of these excipients on lysozyme stability at different concentrations 
of excipients in aqueous media. This was investigated by studying (i) the influences of each 
excipient on the protein stability, integrity and activity in solution forms, (ii) the influence of 
adding two excipients on the stability, integrity and activity of lysozyme in solution forms 
and (iii) the relationship between the increase of excipient concentrations and the activity of 
lysozyme in liquid formulation with various lysozyme concentration. 
  
MATERIALS AND METHODS 
Materials 
Lysozyme was purchased from BBI Enzyme Ltd, UK. Micrococcus Lysodeikticus 
(lyophilised cells) and copovidone poly (1-vinylpyrrolidone-co-vinyl acetate) were obtained 
from Sigma-Aldrich, UK. Gelucire 44/14 was obtained from Gattefossé, France. Crystalline 
milled lactitol was from Cultor Food Science, USA. Sodium hydroxide was obtained from 
VWR International, UK. Sodium chloride was purchased from BDH Chemical Ltd, UK. 
Potassium phosphate, monobasic was purchased from Fisher Scientific, US. All other 
reagents were either of pharmacological or analytical grade.  
 
Protein formulations with a single excipient 
Solutions with different concentrations of lysozyme and excipients (lactitol, copovidone and 
gelucire 44/14) were prepared in 0.076M phosphate buffer, pH 6.6 according to protein: 
excipient weight (g) ratios. The protein: excipient ratios, w/w, were 10:0.1, 10:0.5 and 10:1 in 
100ml buffer, pH 6.6. Blank solutions (containing only excipients) were also prepared for 
each formulation. 
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Protein formulations with two excipients 
Protein formulations containing lysozyme and two excipients were prepared according to the 
protein: combined excipients weight (g) ratios as follow: 1:0.5:0.5, 6: 0.5:0.5 and 10: 0.5:0.5 
in 0.076M phosphate buffer, pH 6.6 (100ml). Mixtures of two excipients (1:1) in the same 
buffer were firstly prepared by combing the following excipients together: lactitol and 
copovidone, lactitol and gelucire 44/14, and copovidone and gelucire 44/14.  
 
Characterisation of lysozyme formulations 
Protein concentration determination 
Protein concentration in the prepared formulations were determined by using UV 
spectrophotometry (CamSpec, UK). The presence of aromatic amino acids (Tyrosine, 
tryptophan and phenylalanine) in the protein structure can be detected at 280 nm. A 
calibration plot was constructed (in lysozyme concentration range of 0.05±0.40 mg/ml) in 
phosphate buffer, 0.067 M, pH 6.6; the squared correlation coefficient value was 0.992. 
 
Biological activity assay for lysozyme 
Lysozyme enzymatic activity can be detected by measurLQJWKHUDWHRIK\GURO\VLVRIȕ-1, 4-
glycosidic linkages between N-acetylglucosamine and N-acetylmuramic acid in bacterial cell 
walls. Using M501 Single beam Scanning UV/Visible spectrophotometer Camspec 
(Biochrom, UK), the biological activity of lysozyme was assayed by following a procedure 
described by Elkordy et al (2002), 100ml of bacterial suspension was freshly prepared by 
mixing 90ml of bacterial suspension (20 mg Micrococcus Lysodeikticus added to 90ml of 
potassium phosphate buffer 0.067 M, pH 6.6) and 10 ml of 1% sodium chloride (NaCl) 
solution. The biological reaction was initiated by adding 0.5 ml of each protein solution 
(lysozyme formulations) in concentration of 1.5 µg/ml prepared in the same buffer to 5ml of 
the bacterial suspension. Lysozyme activity was determined using the following equation 
(Shugar, 1952): 
$FWLYLW\8QLWVPJ ǻQPPLQ(0.001 x mg enzyme in the reaction) (Eq. 1) 
The unit activity of lysozyme was monitored by the reduction in the absorption rate at 450 
nm. 
 
Fluorescence analysis 
Fluorescence spectra were recorded using Perkin Elmer Luminescence Spectrometer (model 
LS50B, made in UK) following an excitation at 350nm and emission of 394nm wavelengths. 
A one cm quartz cell was used. All spectra were recorded using the same conditions: 
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excitation and emission slits were adjusted at 10nm band width and scan speed set at 
500nm/min. The emission scan range was recorded between 370nm and 600nm. 
Fluorescence measurements were recorded for each blank solution prepared for respective 
formulation under identical conditions. The data obtained were processed with FL WinLab 
software (version 4.00.03) (Perkin Elmer, UK). Spekwin32 software, (version 1.71.6.1) was 
used for spectrum subtraction and to identify peak positions. 
 
RESULTS AND DISCUSSION 
Visual inspection of all protein: excipient/s formulations (Table 1) revealed some turbidity in 
the protein solution for the gelucire 44/14 containing samples (Fig. 1) that could be related to 
protein aggregation in solution forms. Accordingly, no further assessment was applied to 
these samples. All protein samples contain gelucire 44/14 as a single excipient exposed white 
gel or turbidity in the solution form. It is documented that, increasing the moisture content of 
gelucire 44/14 forms white gels that are composed of liquid crystalline phases (hexagonal and 
lamellar mesophases) are formed. This gel dissolves at 35 ºC (Svensson et al., 2004). 
However, combination of gelucire 44/14 with lactitol at certain ratios of the protein and 
excipients exhibited different results (see below). 
 
Fig. 1: Lysozyme formulations containing 10% Lysozyme and A) Lactitol and Gelucire 
B) Lactitol and Copovidone C) Copovidone and Gelucire. Solution A and C are omitted 
in the following protein characterisation procedure. 
 
Table 1 shows the percentage concentration of lysozyme content relative to the initial 
concentration of lysozyme added in each formulation (10% lysozyme). For 10% lysozyme: 
excipient/s formulations, two samples only showed 100% of protein content preservation 
(0.1% lactitol and 0.1% copovidone), meaning that at this high protein concentration lactitol 
A B C 
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and copovidone are promising excipients compared to gelucire 44/14. In the other hand, all 
different excipients at their different ratios (% w/v) preserved more than 90% of protein 
concentration either  using the excipient alone or by combining two excipients in the same 
formulation (see Table 1). This study was conducted using ultraviolet spectrophotometry that 
totally depends on the aromatic amino acid residues (tyrosine, tryptophan and/or 
phenylalanine) to absorb the ultraviolet light at a wavelength of 280 nm (Haj-Ahmad et al., 
2013). The presence of protein in a liquid environment can lead to some structural changes in 
these residues and might even affect the whole structure of the protein (Li and Li, 2011). 
Consequently, the presence of some excipients at certain concentration helped to preserve the 
protein content of lysozyme in the liquid form. 
 
Table 1: Formulations, protein content results of lysozyme preparations with and 
without excipients. 
composition Protein content (%)* 
10% Lysozyme with no excipients 93.5 (0.120) 
10% Lysozyme with Lactitol 
Lysozyme with 0.1% Lactitol 103.7 (0.12) 
Lysozyme with 0.5% Lactitol 93.8 (0.24) 
Lysozyme with 1.0% Lactitol 99.0 (0.12) 
10% Lysozyme with Copovidone 
Lysozyme with 0.1% Copovidone 101.1 (0.120) 
Lysozyme with 0.5% Copovidone 97.0 (0.367) 
Lysozyme with 1.0% Copovidone 99.2 (0.367) 
10% Lysozyme with Gelucire 44/14 
Lysozyme with 0.1% Gelucire 44/14 NA 
Lysozyme with 0.5% Gelucire 44/14 NA 
Lysozyme with 1.0% Gelucire 44/14 NA 
Combined excipients 
1% Lysozyme with Lactitol and Copovidone 107.9 (0.615) 
1% Lysozyme with Lactitol and Gelucire 44/14 100.9 (0.127) 
1% Lysozyme with Copovidone and Gelucire 44/14 97.2 (0.248) 
6% Lysozyme with Lactitol and Copovidone 116.5 (0.248) 
 6% Lysozyme with Lactitol and Gelucire 44/14 96.1 (0.106) 
 6% Lysozyme with Copovidone and Gelucire 44/14 100.5 (0.410) 
10% Lysozyme with Lactitol and Copovidone 95.1 (0.488) 
10% Lysozyme with Lactitol and Gelucire 44/14 96.0 (0.495) 
10% Lysozyme with Copovidone and Gelucire 44/14 99.4 (0.127) 
* Values are the mean (standard deviation). 
 
Biological activity of lysozyme is the most important parameter to define how successful are 
the excipients in preserving the integrity and stability of lysozyme. The biological activity 
results of lysozyme were expressed as a percentage ± SD relative to that of the % of 
www.ejbps.com   
 
1334 
Elkordy et al.                     European Journal of Biomedical and Pharmaceutical Sciences 
lysozyme per each formulation (refer to Fig. 2 & 3). For 1% lysozyme: excipients¶ 
formulations, the biological activity of lysozyme was preserved using a combination of 
lactitol and gelucire 44/14 (100% protein activity) and a combination of copovidone and 
gelucire 44/14 (80% protein activity) (Fig. 3). Accordingly, gelucire 44/14 as an excipient 
was effective in preserving the protein integrity and stability when combined with another 
excipients but not alone. For 6% lysozyme: excipient/s formulations: the biological activity 
of lysozyme was maintained by combining lactitol and copovidone in one formulation. For 
10% lysozyme: excipient/s formulations, all concentrations of lactitol or copovidone used as 
a single excipient in formulations showed about 100% biological activity of lysozyme (Fig. 
2). However, the combined excipients in the used concentration (0.5:0.5 w/w in 100ml 
buffer) were not successful to maintain protein biological activity at lysozyme concentration 
of 10%w/v (Fig. 3). The results of the biological activity assay were confirmed by the 
fluorescence analysis of lysozyme formulations results. 
 
Fig. 2: Percentage lysozyme biological activity of formulations containing different type 
of excipient, at different concentration. 
www.ejbps.com   
 
1335 
Elkordy et al.                     European Journal of Biomedical and Pharmaceutical Sciences 
 
Fig 3. Percentage lysozyme biological activity of formulations contains two excipients. 
 
Fluorescence spectroscopy analysis of lysozyme formulations was applied to monitor the 
influences of the used excipients on lysozyme in solution forms by identifying the changes in 
fluorescence intensity. For 10% lysozyme formulations, minor reduction of fluorescents 
intensities were observed for samples with single/combined excipients. For 10% lysozyme 
formulations, the data shows major increases on the fluorescents intensities for 10% 
lysozyme with combined excipients. The folded three dimensional structure of proteins is 
related to its activity. Tryptophan (Trp) is the most important amino acid residue in proteins 
biological activity. Lysozyme contains six tryptophan residues, three of them are located in 
the active site (Trp residues 62, 63 and 108) in which Trp 62 and Trp 108 are the dominant 
emitters (Imoto et al., 1972). Changes in the fluorescent intensity might result from a partial 
loosing of the tight packing around one of the Trp residues in lysozyme active site (Laurents 
and Baldwin, 1997), and this can justify the significant reduction of lysozyme activity in the 
formulations with low biological activity.  
 
The addition of the used excipients in certain percentage to lysozyme (in certain ratio) in 
aqueous phase, reduced and prevented lysozyme aggregation by forming a soluble lysozyme-
excipient/s complex. The possible way of preserving the lysozyme integrity by the used 
excipients could be by interacting with the accessible hydrophobic portion of lysozyme 
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through hydrophobic moiety, hydrogen bonding or van der Waals interactions, thus, 
increased the lysozyme solubility and reduced protein aggregation. Another suggested 
mechanism in which additives can preserve a fully active protein is by preserving the actual 
size of the binding cleft of the protein by the potency of these excipients to replace water 
molecules in the protein active site and make water bridges between different regions within 
the protein molecule. This consequently, preserves the actual size of the binding cleft of the 
protein (Nagendra et al., 1998). 
 
CONCLUSION 
In conclusion, lactitol and copovidone as single and combined excipients successfully 
maintained the biological activity and structural integrity of lysozyme in aqueous 
formulations.  Gelucire 44/14 was only effective upon combining with other excipients such 
as lactitol. Different concentrations of the protein has also an impact on the formulations. 
Accordingly, an optimum concentration of both protein and excipient/s can be utilised to 
formulate a stable and active protein formulation in liquid forms.  
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